Status:

UNKNOWN

Methylene Blue as a Third-line Vasopressor in Septic Shock

Lead Sponsor:

Carilion Clinic

Collaborating Sponsors:

Provepharm Life Solutions

Conditions:

Septic Shock

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

A randomized, prospective study comparing ProvayBlue® to standard care with multiple sympathomimetic vasopressors.

Detailed Description

The study will be an un-blinded, Phase 2, randomized, 1:1, prospective trial comparing patients in septic shock receiving norepinephrine and vasopressin followed by phenylephrine versus ProvayBlue® as...

Eligibility Criteria

Inclusion

  • 1\. Meets Sepsis-3 Criteria (Suspected source of infection plus any 2 criteria of the qSOFA)
  • 2 .Septic Shock (any patient requiring vasopressor therapy to maintain MAP \>65 mmHg or any patient with serum lactate \>2 mmol/dL even in the absence of hypovolemia ).
  • 3\) Greater than 18 years old
  • 4 ) ICU Admission

Exclusion

  • Inability to obtain informed consent from an appropriate surrogate decision maker.
  • Also:
  • Children less than 18 years old
  • Pregnant women or positive urinary pregnancy test in reproductive-aged women
  • Prisoners
  • Evolving myocardial infarction or known cardiomyopathy with documented EF\<35%
  • Known grade 3 diastolic dysfunction document by echocardiogram
  • Known hypersensitivity to thiazine dyes
  • Pulmonary hypertension that is currently requiring vasodilator therapy
  • Concurrent form of shock present or suspected: Obstructive, Neurogenic, Hemorrhagic
  • Known documented history of G6PD deficiency or favism
  • Active prior to admission medication prescription for a SSRI or SNRI , systemic heparin anticoagulation or other medications listed above (under Study Agent). These medications will be listed in the printed enrollment form.
  • Severe renal failure is a contraindication to use of ProvayBlue®.

Key Trial Info

Start Date :

December 1 2019

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

November 1 2024

Estimated Enrollment :

250 Patients enrolled

Trial Details

Trial ID

NCT04089072

Start Date

December 1 2019

End Date

November 1 2024

Last Update

July 26 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Carilion Clinic

Roanoke, Virginia, United States, 24014